Assembly Biosciences (ASMB) Capital Expenditures (2011 - 2026)

Assembly Biosciences' Capital Expenditures history runs 16 years deep, the most recent figure standing at $19000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $19000.0 in Q1 2026; TTM through Mar 2026 was $85000.0, a 507.14% increase from a year earlier, with the FY2025 full-year figure at $66000.0, up 135.71% from the prior year.
• Capital Expenditures slipped to $19000.0 in Q1 2026 per ASMB's latest filing, from $24000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $741000.0 in Q3 2023 and bottomed at -$916000.0 in Q4 2022.
• The 5-year median for Capital Expenditures is $16500.0 (2024), against an average of -$106500.0.
• Across the five-year window, Capital Expenditures plunged 5188.89% in 2022 and soared 335.88% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at -$916000.0 in 2022, then rose by 16.92% to -$761000.0 in 2023, then surged by 101.84% to $14000.0 in 2024, then jumped by 71.43% to $24000.0 in 2025, then fell by 20.83% to $19000.0 in 2026.
• Per Business Quant, the three latest ASMB Capital Expenditures figures stand at $19000.0 (Q1 2026), $24000.0 (Q4 2025), and $42000.0 (Q3 2025).